We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Rises As Market Takes a Dip: Key Facts
Read MoreHide Full Article
Merck (MRK - Free Report) closed at $111.53 in the latest trading session, marking a +1.68% move from the prior day. The stock's change was more than the S&P 500's daily loss of 0.76%. Elsewhere, the Dow lost 0.75%, while the tech-heavy Nasdaq lost 1.01%.
Coming into today, shares of the pharmaceutical company had lost 7.01% in the past month. In that same time, the Medical sector lost 3.35%, while the S&P 500 gained 4.31%.
The upcoming earnings release of Merck will be of great interest to investors. The company's earnings report is expected on October 31, 2024. The company is expected to report EPS of $1.59, down 25.35% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $16.5 billion, showing a 3.36% escalation compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $7.85 per share and revenue of $64.11 billion, which would represent changes of +419.87% and +6.65%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Merck. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 1.95% lower. Merck is currently a Zacks Rank #3 (Hold).
Looking at its valuation, Merck is holding a Forward P/E ratio of 13.97. This indicates a discount in contrast to its industry's Forward P/E of 15.88.
Investors should also note that MRK has a PEG ratio of 1.55 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.65 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 33, placing it within the top 14% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRK in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merck (MRK) Rises As Market Takes a Dip: Key Facts
Merck (MRK - Free Report) closed at $111.53 in the latest trading session, marking a +1.68% move from the prior day. The stock's change was more than the S&P 500's daily loss of 0.76%. Elsewhere, the Dow lost 0.75%, while the tech-heavy Nasdaq lost 1.01%.
Coming into today, shares of the pharmaceutical company had lost 7.01% in the past month. In that same time, the Medical sector lost 3.35%, while the S&P 500 gained 4.31%.
The upcoming earnings release of Merck will be of great interest to investors. The company's earnings report is expected on October 31, 2024. The company is expected to report EPS of $1.59, down 25.35% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $16.5 billion, showing a 3.36% escalation compared to the year-ago quarter.
For the full year, the Zacks Consensus Estimates are projecting earnings of $7.85 per share and revenue of $64.11 billion, which would represent changes of +419.87% and +6.65%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Merck. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 1.95% lower. Merck is currently a Zacks Rank #3 (Hold).
Looking at its valuation, Merck is holding a Forward P/E ratio of 13.97. This indicates a discount in contrast to its industry's Forward P/E of 15.88.
Investors should also note that MRK has a PEG ratio of 1.55 right now. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.65 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 33, placing it within the top 14% of over 250 industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRK in the coming trading sessions, be sure to utilize Zacks.com.